The rationale for using dual checkpoint inhibitors is to achieve a more robust and sustained anti-cancer response. While single checkpoint inhibitors, such as those targeting PD-1 or CTLA-4, have shown effectiveness, combining two inhibitors can potentially overcome resistance mechanisms that tumors develop against monotherapies.
